Medexus Pharmaceuticals (TSE:MDP) Cut to Hold at Stifel Nicolaus

Stifel Nicolaus lowered shares of Medexus Pharmaceuticals (TSE:MDP) from a buy rating to a hold rating in a report released on Friday morning,BayStreet.CA reports. Stifel Nicolaus currently has C$3.45 target price on the stock, down from their previous target price of C$6.00.

A number of other brokerages also recently commented on MDP. Ventum Cap Mkts raised shares of Medexus Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 17th. Raymond James raised shares of Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 price objective on the stock in a research report on Wednesday, January 8th. Alliance Global Partners upgraded shares of Medexus Pharmaceuticals to a “strong-buy” rating in a report on Monday, December 23rd. Leede Financial raised shares of Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, January 22nd. Finally, Ventum Financial raised their target price on shares of Medexus Pharmaceuticals from C$5.00 to C$6.25 and gave the company a “buy” rating in a research report on Thursday, January 30th. Two equities research analysts have rated the stock with a hold rating, one has given a buy rating and four have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of C$5.49.

Medexus Pharmaceuticals Price Performance

TSE MDP opened at C$3.21 on Friday. The stock has a market capitalization of C$78.74 million, a PE ratio of 64.20 and a beta of 1.96. Medexus Pharmaceuticals has a 1-year low of C$1.47 and a 1-year high of C$5.56. The business has a 50 day simple moving average of C$3.54 and a two-hundred day simple moving average of C$2.83.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.